GlassScriptPhysician profile
Kevin Scott Berman
NPI 1336118983
$16,613.73
in general payments reported to CMS, 2019-2025
39 companies · $3,875 in 2025
The $3,875 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $1,175 · 2021: $2,244 · 2022: $2,421 · 2023: $2,226 · 2024: $2,884 · 2025: $3,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,729 · Travel and Lodging: $600 · Consulting Fee: $450 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,729.09 |
| Travel and Lodging | $599.69 |
| Consulting Fee | $450.00 |
| Education | $205.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,241.08 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $1,831.09 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,683.73 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,488.11 | 2019-2025 | |
| Lilly USA, LLC | $1,061.79 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $1,009.67 | 2019-2025 | |
| Janssen Biotech, INC. | $886.63 | 2020-2025 | Tremfya |
| Ucb, INC. | $681.94 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $603.52 | 2020-2025 | Otezla, Otezla |
| Intuitive Surgical, INC. | $599.69 | 2025 | |
| Pfizer INC. | $592.28 | 2019-2025 | |
| Journey Medical Corporation | $420.82 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $375.00 | 2019-2025 | Jublia |
| Galderma Laboratories, L.P. | $318.84 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $304.87 | 2021-2025 | Sotyktu |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.